Cachexia is a complex metabolic syndrome characterised by severe involuntary weight loss, muscle wasting, fatigue, weakness, and anorexia. It occurs in the context of serious underlying illness — most commonly cancer, HIV/AIDS, chronic kidney disease, heart failure, and advanced inflammatory conditions such as Crohn's disease. Cachexia is not simply undernutrition; it involves a systemic inflammatory response that cannot be fully reversed by increased caloric intake alone. Medical cannabis — particularly THC — has one of its most established evidence bases in this area.

Understanding Cachexia and Wasting Syndrome

Clinicians distinguish between three overlapping states: pre-cachexia (early metabolic changes and involuntary weight loss of less than 5%), cachexia (weight loss greater than 5%, or greater than 2% in patients already with low BMI, combined with reduced muscle mass and systemic inflammation), and refractory cachexia (seen in advanced cancer where the underlying disease is no longer responding to treatment). The refractory stage is associated with very short expected survival, and treatment goals shift to comfort and quality of life.

In cancer specifically, up to 80% of patients with advanced disease develop cachexia. In HIV/AIDS, wasting syndrome was historically a major cause of morbidity before antiretroviral therapy, and it remains relevant in patients with incomplete immune reconstitution or treatment-resistant infection. In Crohn's disease, malabsorption and systemic inflammation both contribute to weight loss and muscle wasting.

The Role of THC in Appetite Stimulation

Cannabinoid receptors — particularly CB1 receptors — are expressed in hypothalamic circuits governing appetite and energy balance. THC activates these receptors and produces well-documented orexigenic effects: increased appetite, heightened sensory perception of food, and reduced nausea. This mechanism is the basis for two licensed cannabis-derived medicines that pre-date the broader medical cannabis framework: dronabinol (synthetic THC, licensed in the United States for AIDS-related anorexia and chemotherapy-induced nausea) and nabilone (synthetic THC analogue, licensed in the UK for chemotherapy-induced nausea).

Nabilone (Cesamet) has been available on NHS prescription in the UK for chemotherapy-related nausea for decades and represents the longest-standing cannabinoid medicine in UK clinical practice. This provides important context: cannabinoid-based appetite stimulation is not an experimental or fringe concept. It is a pharmacologically established mechanism with a regulatory track record. UK specialists prescribing cannabis-based medicines for cachexia and anorexia are building on this foundation with whole-plant products that provide THC alongside other cannabinoids.

Evidence From Clinical Studies

Clinical evidence for cannabinoids in cachexia is mixed in terms of large trial outcomes, but several important findings exist. Randomised controlled trials of dronabinol in HIV-related wasting and cancer anorexia have demonstrated improvement in appetite and, in some studies, stabilisation of weight. A landmark trial in cancer cachexia published in the Journal of Clinical Oncology found that cannabis extract did not outperform placebo on the primary endpoint of appetite, though this trial used a cannabis extract formulation and a patient population with very advanced disease. The Cochrane review of cannabinoids for chemotherapy-induced nausea and vomiting (updated 2015) found cannabinoids to be more effective than placebo and some comparators.

In practice, UK prescribers consider the totality of evidence alongside individual patient circumstances. For patients with cancer-related anorexia or HIV wasting who have not achieved adequate relief from standard antiemetics, nutritional support, or megestrol acetate, cannabis-based medicines represent a clinically reasonable option within the unlicensed specialist prescribing framework.

Who Qualifies for a Cannabis Prescription for Cachexia in the UK?

Cachexia associated with serious illness is an accepted indication within UK specialist prescribing practice. The relevant clinical criteria are: confirmed underlying diagnosis contributing to cachexia; documented evidence that conventional appetite-stimulating agents (such as megestrol acetate or corticosteroids for short-term use) have been trialled or are contraindicated; and a specialist assessment confirming that cannabis-based medicine is appropriate given the patient's overall clinical picture.

This is not a condition where a patient can self-refer based on wanting appetite stimulation for other reasons. The indication is specifically cachexia and medically documented anorexia in the context of serious illness. Patients seeking prescriptions should expect a thorough clinical assessment.

What to Expect From Treatment

Cannabis-based medicines for cachexia in the UK typically involve THC-containing oils, with dose titration starting low to manage psychoactive effects. Patients and carers should be aware that THC will have psychoactive effects, which may be significant at doses needed for meaningful appetite stimulation, particularly in patients who are elderly, cachectic, or have not previously used cannabis. The prescribing specialist will titrate carefully, and a period of dose adjustment should be expected.

Cannabis-based medicines are not a cure for cachexia. They do not address the underlying inflammatory mechanisms driving muscle catabolism. Their role is palliative — improving appetite, reducing nausea, potentially improving mood and quality of life, and in some cases supporting weight stabilisation. They should be understood as one component of a broader palliative or supportive care plan that includes nutritional support, physiotherapy where appropriate, and management of the underlying condition.

Accessing Treatment

Palliative care specialists, oncologists, and infectious disease consultants are often well placed to initiate referral or prescribing for cachexia-related cannabis use. Private cannabis clinics with experience in oncology or palliative medicine can also prescribe independently. See the UK medical cannabis clinics section for prescribers with relevant experience. For an overview of the prescription process, see how to get a medical cannabis prescription in the UK.

Frequently Asked Questions — Medical Cannabis for Cachexia UK

Is cachexia an approved indication for medical cannabis in the UK?

There is no single NHS-approved indication list for cannabis-based medicines. Cachexia — particularly in the context of cancer, HIV, and serious chronic illness — is an accepted area for specialist prescribing under the unlicensed framework. A GMC-registered specialist can prescribe when conventional treatments have been tried or are contraindicated, and the clinical picture supports it.

What is the difference between cachexia and simply losing weight?

Cachexia involves a systemic inflammatory response that causes the body to break down muscle tissue even when caloric intake is maintained. It cannot be fully reversed by eating more. This distinguishes it from simple undernutrition or diet-related weight loss, and it explains why high-calorie supplementation alone is often inadequate treatment.

Can cannabis-based medicines reverse muscle wasting?

Cannabis-based medicines, particularly THC, can stimulate appetite, reduce nausea, and in some patients support weight stabilisation. They do not directly reverse the underlying inflammatory mechanism driving muscle catabolism. Their role is palliative and supportive, not disease-modifying for cachexia itself.

Is nabilone the same as medical cannabis?

Nabilone is a synthetic THC analogue licensed in the UK for chemotherapy-induced nausea. It is a cannabinoid medicine with a long track record of NHS prescribing. Whole-plant cannabis-based medicines prescribed under the unlicensed framework differ in that they contain a broader range of cannabinoids. Your prescribing specialist will advise on which formulation is appropriate for your situation.

Can a palliative care team refer me for medical cannabis for cachexia?

Yes. Palliative care consultants can prescribe directly under the unlicensed specialist framework, and they can also refer patients to private cannabis clinics with palliative medicine experience. If you are under a palliative care team, raising the question of cannabis-based medicines with your consultant is an appropriate starting point.